Mabgeek Biotech has obtained the clinical approval for its antibody drug for IgA nephritis.
2023-06-15 0
On June 15, 2023, the clinical trial application for the antibody drug "MG-013 humanized monoclonal antibody injection" submitted by Mabgeek Biotech was accepted, and it is intended to be developed for the treatment of IgA nephritis and aHUS.
Image source: CDE official website